3rd Quarter - Report

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Firm
Client
Income
—
Expenses
$3,680,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation H.R. 2024, End Anonymous Patents Act: Patent owner information provisions H.R. 2582, PATENT Jobs Act: Provisions related to patent user fees H.R. 2605, Manufacturing Innovation in America Act of 2013: Provisions related to patent tax boxes H.R. 2639, Patent Litigation and Innovation Act: Patent litigation proposals H.R. 2766, STOP Act: Provisions related to business method patents H.R. 2985, Combination Drug Development Incentive Act of 2013: Provisions related to exclusivity H.R. 3116, MODDERN Cures Act of 2013: Provisions related to exclusivity H.R. 3309, Innovation Act: Provisions related to patent litigation reform H.R. 3349, Innovation Protection Act: PTO Fee Diversion H.R. 3540, Demand Letter Transparency Act: Provisions related to patent demand letters H.R. 3709, Protecting Consumer Access to Generic Drugs: Provisions related to patent settlements H,R, 4287, Independent Innovator and Repurposing Act: Provisions related to patent term restoration H.R. 4763, Trade Protection not Troll Protection Act: Patent and trade provisions H.R. 5233, Trade Secrets Protection Act of 2014: Provisions related to trade secrets S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 626, Prize Fund for HIV/AIDS Act: Medical prize provisions S. 627, Medical Innovation Prize Fund Act: Medical prize provisions S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions S. 1612, Patent Litigation Integrity Act: Patent litigation provisions including bonding S. 1720, Patent Transparency and Improvements Act S, 2049, Transparency in Assertion of Patents Act: Provisions related to patent demand letters S.2150, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 2196, Patent Fee Integrity Act: Patent fee diversion prohibition S. 2267, Defend Trade Secrets Act of 2014: Provisions related to trade secrets Biopharmaceutical innovation policy issues Biologics data protection issues Draft legislation on demand letters, including Targeting Rogue and Opaque Letters (TROL) Act Issues related to biopharmaceutical economic incentives and intellectual property

Contacted: Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); SENATE; Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES

Bills named: H.R. 3349 (113th), S. 626 (113th), H.R. 3540 (113th), H.R. 2766 (113th), S. 712 (113th), H.R. 3709 (113th), S. 214 (113th), H.R. 2582 (113th), H.R. 2639 (113th), S. 627 (113th), H.R. 5233 (113th), H.R. 3116 (113th), S. 2196 (113th), S. 2267 (113th), S. 1612 (113th), S. 866 (113th), H.R. 2985 (113th), S. 504 (113th), H.R. 2024 (113th), H.R. 3309 (113th), H.R. 845 (113th), S. 2150 (113th), S. 1013 (113th), S. 1720 (113th), H.R. 2605 (113th), H.R. 4763 (113th)

Health Issues HCR

H.R. 3742, Antibiotic Development to Advance Patient Treatment Act: Provisions related to antibiotics and drug approval H.R. 4709, Ensuring Patient Access and Effective Drug Enforcement Act: Provisions related to the Controlled Substances Act, Drug Enforcement Agency (DEA) regulation and related issues (a reintroduced version of H.R. 4069) H.R. 4299, Improving Regulatory Transparency for New Medical Therapies Act: Provisions related to DEA scheduling H.R. 5214, To require the Secretary of Health and Human Services to provide for recommendations for the development and use of clinical data registries for the improvement of patient care H.R. 5657, Fair Access for Safe and Timely (FAST) Generics Act: Provisions related to DEA scheduling S. 1723, No ObamaCare Kickbacks Act of 2013: Provisions related to application of the anti-kickback statute to qualified health plans S. 2295, Patient Safety and Generic Labeling Improvement Act: Provisions relating to drug safety labeling (112th Congress) Implementation issues related to the Food and Drug Administration Safety and Innovation Act (Public Law 112-144), including user fee reauthorization and FDA reform Implementation issues related to the Drug Quality and Security Act (Public Law 113-54), including pharmacy compounding and supply chain issues Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including PPACA; Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking 21st Century Cures legislation and policy issues Draft legislation relating to prescription drug coverage issues Issues related to value and cost of prescription drugs Issues related to user fee reauthorization and FDA reform Patient savings program policy issues Comparative effectiveness policy issues Academic detailing policy issues General HHS, NIH, and FDA related advocacy Biopharmaceutical innovation policy issues Prescription drug abuse policy issues FDA accelerated approval policy issues Unapproved use policy issues 340B policy issues Importation policy issues Clinical trial policy issues

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); SENATE; Food & Drug Administration (FDA); Commerce, Dept of (DOC)

Bills named: H.R. 4069 (113th), H.R. 4299 (113th), H.R. 5657 (113th), H.R. 3742 (113th), H.R. 5214 (113th), H.R. 4709 (113th), S. 1723 (113th), S. 2295 (113th)

Medicare/Medicaid MMM

H.R. 351, Protecting Seniors Access to Medicare Act of 2013: Provisions related to the Independent Payment Advisory Board H.R. 460, Patients Access to Treatments Act: Provisions related to cost sharing in the specialty tier H.R. 928, Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to Part D issues H.R. 1024, Medication Therapy Management Empowerment Act of 2013: Provisions related to medication therapy management in Part D H.R. 1102, Medicare Prescription Drug Price Negotiation Act of 2013: Provisions related to Part D issues and non-interference H.R. 1588, Medicare Drug Savings Act of 2013: Provisions related to Part D issues H.R. 2753 Securing Care for Seniors Act: Provisions related to Value Based Insurance Design H.R. 2810, Medicare Patient Access and Quality Improvement Act: Provisions related to SGR reform H.R. 2827, To amend title XVIII of the Social Security Act to allow for fair application of the exceptions process for drugs in tiers in formularies in prescription drug plans under Medicare part D: Provisions related to Medicare Part D Drug Tier Formularies H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act of 2013: Provisions related to fraud and abuse H.R. 3392, Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013: Provisions related to lock-in programs H.R. 3796, Comprehensive Care Payment Innovation Act: Provisions related to alternative payment models H.R. 3890 Better Care, Lower Cost Act: Provisions related to Part D, value-based insurance design, and chronic disease H.R. 4015, SGR Repeal and Medicare Provider Payment Modernization Act of 2014: Provisions related to sustainable growth rate (SGR) and Medicare provider payment reform H.R. 4160, Keep the Promise to Seniors Act of 2014: Provisions related to Part D issues H.R. 4302, Protecting Access to Medicare Act of 2014: Provisions related to the biopharmaceutical industry H.R. 4577, Ensuring Seniors Access to Local Pharmacies Act of 2014: Provisions related to Part D preferred pharmacy networks H.R. 5183, Value Based Insurance Design for Better Care Act of 2014: Provisions related to valued base insurance design demonstration program H.R. 5558 ACO Improvement Act: Provisions related to alternate payment models S. 117, Medicare Prescription Drug Price Negotiation Act of 2013: Provisions related to Part D issues and non-interference S. 351, Protecting Seniors Access to Medicare Act of 2013: Provisions related to Independent Payment Advisory Board S. 408, Medicare Prescription Drug Savings and Choice Act of 2013: Provision related to Part D issues S. 557, Medication Therapy Management Empowerment Act of 2013: Provisions related to Part D and medication therapy management S. 740, Medicare Drug Savings Act of 2013: Provisions related to Part D issues Deficit reduction policy issues S. 882, Stop Trafficking of Pills (STOP) Act: Provisions related to lock-in programs (112th Congress) S. 1365, Part D Beneficiary Appeals Fairness Act: Provisions related to the specialty tier in Part D S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013: Provisions related to reforming Medicare physician payments S. 1932, Better Care, Lower Cost Act: Provisions related to Part D, value-based insurance design, and chronic disease S. 2000, SGR Repeal and Medicare Provider Payment Modernization Act of 2014: Provisions related to SGR reform S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014: Provisions related to SGR reform Medicare Prescription Drug Diversion and Abuse Prevention Act: Provisions related to diversion and abuse (no bill number) Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefits Programs: Provisions related to Part D Proposals to increase co-payments for Part D beneficiaries receiving the low-income subsidy Medicaid Program, Covered Outpatient Drugs rulemaking Medicare sustainable growth rate policy issues Implementation issues relating to the Physician Payment Sunshine Act, including Medicare, Medicaid, Childrens Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests rulemaking Issues related to better use of medicine and adherence Protecting Integrity in Medicare Act of 2014 (no bill number): Provisions related to addressing fraud, prescription drug abuse, and other issues Lock-in concepts generally

Contacted: Health & Human Services, Dept of (HHS); SENATE; Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Medicare Payment Advisory Commission (MedPAC); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 5558 (113th), H.R. 2753 (113th), H.R. 460 (113th), S. 1932 (113th), S. 882 (113th), H.R. 2827 (113th), S. 557 (113th), H.R. 2925 (113th), H.R. 351 (113th), H.R. 3890 (113th), S. 408 (113th), S. 740 (113th), H.R. 1102 (113th), H.R. 4577 (113th), H.R. 4160 (113th), H.R. 1024 (113th), H.R. 5183 (113th), S. 1365 (113th), S. 2000 (113th), H.R. 928 (113th), H.R. 3796 (113th), H.R. 4015 (113th), S. 117 (113th), H.R. 2810 (113th), S. 2110 (113th), H.R. 4302 (113th), S. 1871 (113th), H.R. 3392 (113th), H.R. 1588 (113th), S. 351 (113th)

Budget/Appropriations BUD

H.R. 3230, Veterans Access to Care through Choice, Accountability, and Transparency Act of 2014: Provisions related to TRICARE health care program H.R. 4486, Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2015: Provisions related to TRICARE health care program H.R. 4660, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2015: Provisions related to United State Trade Representative (USTR) and Patent and Trademark Office (PTO) H.R. 4800, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015: Provisions related to Food and Drug Administration (FDA) funding and oversight H.R. 4870, Department of Defense Appropriations Act, 2015: Provisions related to defense health programs and bio-defense H.R. 4903, Department of Homeland Security Appropriations Act, 2015: Provisions related to Customs and Border security FY 2015 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act: Provisions related to 340B Drug Pricing Program, National Institutes of Health (NIH), Independent Payment Advisory Board (IPAB), Agency for Healthcare Research & Quality (AHQR) (no bill number) H.J. Res. 124, Continuing Appropriations Resolution

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); SENATE; Patent & Trademark Office (PTO); Commerce, Dept of (DOC); Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.J.Res. 124 (113th), H.R. 4870 (113th), H.R. 4903 (113th), H.R. 4800 (113th), H.R. 4486 (113th), H.R. 4660 (113th), H.R. 3230 (113th)

Trade (domestic/foreign) TRD

H.R. 3167, Playing Fair on Trade and Innovation Act: Provisions related to intellectual property H.R. 3803, Bipartisan Congressional Trade Priorities Act of 2014: Provisions related to trade agreements H.R. 4763, Trade Protection not Troll Protection Act: Patent and trade provisions S. 1900, Bipartisan Congressional Trade Priorities Act of 2014: Trade promotion authority issues Korea Free Trade Agreement: Implementation issues related to intellectual property, market access and public health Trans-Pacific Partnership (TPP): Provisions related to intellectual property, market access and public health issues Mexico and Canada IP and market access issues Turkey Market Access Issues India innovation, IP and market access issues Transatlantic Trade and Investment Partnership (TTIP): Market access, intellectual property, regulatory and other issues The Agriculture Reform, Food and Jobs Act of 2013/H.R. 1947, Federal Agriculture Reform and Risk Management Act of 2013: Issues related to World Trade Organization (WTO) Brazil Cotton dispute Issues related to Special 301 and National Trade Estimate (NTE) submissions including intellectual property and market access issues China intellectual property and market access issues International market access and intellectual property issues Biopharmaceutical innovation policy issues Trade Promotion Authority policy issues Generalized System of Preferences policy issues Colombia biosimilars policy issues

LobbyistCovered position, as disclosed
JOHN J CASTELLANI —
CHESTER (CHIP) DAVIS —
LEA FISHER —
JEFFREY FRANCER —
DAVID KORN —
COLLEEN MALONEY —
NICK SHIPLEY —
JAMES M SPEARS —

Contacted: Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); SENATE; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Food & Drug Administration (FDA)

Bills named: S. 1900 (113th), H.R. 3803 (113th), H.R. 4763 (113th), H.R. 3167 (113th), H.R. 1947 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.